Atomoxetine on neurogenic orthostatic hypotension: a randomized, double-blind, placebo-controlled crossover trial
Clinical Autonomic Research · 2024
DOI: 10.1007/s10286-024-01051-2 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Autonomic Research, 2024. Verfasst von Naome Mwesigwa und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, 506 Robinson Research Building, Nashville, TN, 37232…. Hauptthemen laut MEDLINE: Atomoxetine Hydrochloride, Hypotension, Orthostatic, Cross-Over Studies, Adrenergic Uptake Inhibitors. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Center for Clinical and Translational Science, University of Illinois at Chicago, U.S. Food and Drug Administration, National Center for Research Resources FDA Office for Orphan Product Development.
Abstract (Originalsprache)
Purpose
We previously reported that single doses of the norepinephrine transporter inhibitor, atomoxetine, increased standing blood pressure (BP) and ameliorated symptoms in patients with neurogenic orthostatic hypotension (nOH). We aimed to evaluate the effect of atomoxetine over four weeks in patients with nOH.
Methods
A randomized, double-blind, placebo-controlled crossover clinical trial between July 2016 and May 2021 was carried out with an initial open-label, single-dose phase (10 or 18 mg atomoxetine), followed by a 1-week wash-out, and a subsequent double-blind 4-week treatment sequence (period 1: atomoxetine followed by placebo) or vice versa (period 2). The trial included a 2-week wash-out period. The primary endpoint was symptoms of nOH as measured by the orthostatic hypotension questionnaire (OHQ) assessed at 2 weeks.
Results
A total of 68 patients were screened, 40 were randomized, and 37 completed the study. We found no differences in the OHQ composite score between atomoxetine and placebo at 2 weeks (−0.3 ± 1.7 versus −0.4 ± 1.5; P = 0.806) and 4 weeks (−0.6 ± 2.4 versus −0.5 ± 1.6; P = 0.251). There were no differences either in the OHSA scores at 2 weeks (3 ± 1.9 versus 4 ± 2.1; P = 0.062) and at 4 weeks (3 ± 2.2 versus 3 ± 2.0; P = 1.000) or in the OH daily activity scores (OHDAS) at 2 weeks (4 ± 3.0 versus 5 ± 3.1, P = 0.102) and 4 weeks (4 ± 3.0 versus 4 ± 2.7, P = 0.095). Atomoxetine was well-tolerated.
Conclusions
While previous evidence suggested that acute doses of atomoxetine might be efficacious in treating nOH; results of this clinical trial indicated that it was not superior to placebo to ameliorate symptoms of nOH.
Trial registration
ClinicalTrials.gov; NCT02316821.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, 506 Robinson Research Building, Nashville, TN, 37232-8802, USA.
- Department of Neurology, New York University Grossman School of Medicine, New York, NY, USA.
- Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, 506 Robinson Research Building, Nashville, TN, 37232-8802, USA. Cyndya.shibao@vumc.org.
Förderung
- Center for Clinical and Translational Science, University of Illinois at Chicago
- U.S. Food and Drug Administration
- National Center for Research Resources FDA Office for Orphan Product Development
Zitieren
APA
Mwesigwa, N., Millar Vernetti, P., Kirabo, A., Black, B., Ding, T., Martinez, J., Palma, J. A., Biaggioni, I., Kaufmann, H., & Shibao, C. A. (2024). Atomoxetine on neurogenic orthostatic hypotension: a randomized, double-blind, placebo-controlled crossover trial. Clinical Autonomic Research. https://doi.org/10.1007/s10286-024-01051-2
Vancouver
Mwesigwa N, Millar Vernetti P, Kirabo A, Black B, Ding T, Martinez J, et al. Atomoxetine on neurogenic orthostatic hypotension: a randomized, double-blind, placebo-controlled crossover trial. Clinical Autonomic Research. 2024. doi:10.1007/s10286-024-01051-2
BibTeX
@article{Mwesigwa2024,
author = {Mwesigwa, Naome and Millar Vernetti, Patricio and Kirabo, Annet and Black, Bonnie and Ding, Tan and Martinez, Jose and Palma, Jose-Alberto and Biaggioni, Italo and Kaufmann, Horacio and Shibao, Cyndya A},
title = {Atomoxetine on neurogenic orthostatic hypotension: a randomized, double-blind, placebo-controlled crossover trial},
journal = {Clinical Autonomic Research},
year = {2024},
doi = {10.1007/s10286-024-01051-2}
}
EUVIMED